X
XO1
Virtual biotechnology company formed specifically to develop ichorcumab
About XO1
XO1 Limited is a virtual biopharmaceutical company focused on developing ichorcumab, an innovative antibody targeting thrombin to provide anticoagulation without the risk of bleeding. The company operates in the biopharmaceutical sector, primarily serving healthcare providers and patients who require anticoagulation therapy. XO1's business model revolves around the research and development of this unique therapeutic solution, which aims to address a significant unmet medical need. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The market for anticoagulation therapies is substantial, given the prevalence of conditions like deep vein thrombosis and pulmonary embolism, which require effective and safe anticoagulation treatments. XO1's acquisition by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, underscores the strategic value and potential impact of its core product, ichorcumab.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- London, United Kingdom
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 55.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2015 | $0 | — | Johnson & Johnson Innovative Medicine | — |
| SERIES AOther financing | Jun 2013 | $11M | $44M | Index Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for XO1 is 0 monthly website visits. XO1's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors2 additional known investors
Johnson & Johnson Innovative Medicine
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about XO1 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See XO1’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.